Research Projects

PRIME introduces the novel concept of insulin signalling as a key mechanism underlying the multimorbidity of major mental and somatic illnesses. It is well known that aberrant insulin signalling causes high health and socioeconomic burden through its role in diabetes, metabolic syndrome, and obesity. We posit that the impact of ‘insulinopathies’ is...

Alzheimer’s disease (AD) is the leading cause of dementia and loss of autonomy in the elderly, implying a progressive cognitive decline and limitation of social activities. Progressive aging of EU population will increase the magnitude of this problem in the next decades. Currently, there is not an effective method for the early diagnosis of AD...

The current nosology of neuropsychiatric disorders allows for a pragmatic approach to treatment choice, regulation and clinical research. However, without a biological rationale for these disorders, drug development has dramatically stagnated in the past decades. In a coordinated effort encompassing academic experts, SMEs, patient and family...

The overall prevalence of brain disorders – both neurological and psychiatric – is very high in Europe. Although it is well known that the burden and costs of these disorders are high, there is evidence that the overall, personal, social and economic costs of brain disorders have been underestimated because of the lack of valid and reliable...

Alzheimer’s disease is on the rise in our ageing population, and new, effective treatments are urgently needed. Currently, the safety and benefits to patients of potential treatments are assessed in strictly-controlled clinical trials. However, clinical trials do not provide information on the health benefits for patients in their daily lives in...

Alzheimer's disease (AD), the main cause of dementia, is one of the major global health challenges of our time. This disabling disorder affects 55 million people worldwide, with costs above $1.3 trillion. With 67 million people at risk for AD dementia (prodromal and preclinical AD) in Europe alone, it is a major unmet public health need, with...

In recent years there is mounting evidence that type 2 diabetes (T2D) is associated with cognitive impairment and dementia, which can be considered as a “new” long-term diabetic co-morbid complication with dramatic consequences for patients and their families and a significant impact for healthcare systems. At present there are no reported...

RAMCIP will research and develop a novel domestic service robot, with the aim to proactively and discreetly assist older persons, MCI and AD patients in their every day life. Instead of simply being an obedient servant, the RAMCIP robot will have high-level cognitive functions, driven through advanced human activity and home environment modelling...

Alzheimer’s disease (AD) is an irreversible neurodegenerative condition affecting 50 million people worldwide. Despite intense research, the pathological mechanisms of AD are still unclear. Many genetic loci robustly associated with AD code for proteins that are preferentially or exclusively expressed in microglia, supporting a causal role of...

According to the World Health Organisation (WHO, ADI), 44 million people around the world have some form of dementia, for which there is no effective intervention, to halt or reverse the progressive cognitive impairment. As Europe’s population is ageing, long-term care for elderly citizens will become an increasing cost for society. To manage this...

This project brings together a diverse group of subject matter experts from industry and academia under one umbrella, with the main aim of enhancing and advancing future healthcare processes and systems using sensory and machine learning technologies to provide emotional (affective) and cognitive insights into patients well-being so as to provide...

Direct quantification of dopamine neurotransmission is one of the unsolved problems that engaged scientific minds for the last fifty years. Such quantification is an extremely important tool to understand the underlying pathways that promote neurodegenerative diseases like Alzheimer's and depression. Since dopamine is secreted only in micro-molar...